From 24/7 Wall St. · Omor Ibne Ehsan · · 1m 40s
Eli Lilly's obesity bet hinges on September 30 data
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble.
In brief
A two-drug combo could justify Lilly's trillion-dollar valuation, but the mid-stage trial results will determine if it's a breakthrough or an expensive gamble. Eli Lilly's stock valuation leaves almost no room for disappointment in the eloraTZP trial results on September 30, with discontinuation rates and dose…
Lilly's trillion-dollar bet on a combo drug
Eli Lilly presents mid-stage data on eloraTZP, combining eloralintide and tirzepatide, at a European diabetes symposium on September 30. The stock trades near $1,152 based on obesity-franchise expectations with little room for disappointment.
What the data must prove
Watch four metrics: weight loss magnitude, dose arms, tolerability, and discontinuation rates. The combination must separate from each individual component, not just placebo, or the strategic rationale weakens.
Mounjaro and Zepbound dominate the market
Mounjaro and Zepbound generated $14.87 billion in the second quarter, with Mounjaro up 91% year over year. That scale outpaces Novo Nordisk, whose GLP-1 franchise faces headwinds.
The valuation already assumes success
Lilly trades at a forward earnings multiple of 24x and a market cap near $1.01 trillion. Options markets show caution with put/call ratios of 2.33 for October 2 and 4.67 for October 9.
Bull case: franchise extension
If eloraTZP shows meaningfully deeper weight loss than tirzepatide alone with clean tolerability, it defends the franchise as retatrutide moves toward a Q1 2027 submission. CEO David Ricks raised guidance to $85.0 to $87.0 billion in full-year revenue.
Bear case: expensive line extension
If eloraTZP matches Zepbound efficacy, shows worse GI tolerability, or has higher discontinuations, the combo becomes redundant. Analyst targets average $1,324.87, offering modest cushion against a $1 trillion base.
What it means
Eli Lilly's stock valuation leaves almost no room for disappointment in the eloraTZP trial results on September 30, with discontinuation rates and dose separation from tirzepatide alone being the deciding factors.
